Protalix BioTherapeutics
PLX
PLX
99 hedge funds and large institutions have $36.1M invested in Protalix BioTherapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
19% more funds holding
Funds holding: 83 → 99 (+16)
2.13% more ownership
Funds ownership: 18.53% → 20.66% (+2.1%)
Holders
99
Holding in Top 10
–
Calls
$651K
Puts
$383K
Top Buyers
| 1 | +$8.79M | |
| 2 | +$1.04M | |
| 3 | +$962K | |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$665K |
| 5 |
Morgan Stanley
New York
|
+$421K |
Top Sellers
| 1 | -$5.31M | |
| 2 | -$788K | |
| 3 | -$676K | |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$378K |
| 5 |
Barclays
London,
United Kingdom
|
-$243K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
101
HRT Financial
New York
| – |
|
|||
|
TSS
102
Two Sigma Securities
New York
| – |
|
|||
|
XT
103
XTX Topco
George Town,
Cayman Islands
| – |
|
|||
104
Marshall Wace
London,
United Kingdom
| – |
|
|||
105
SG Americas Securities
New York
| – |
|
|||
|
RS
106
R Squared
Central,
Hong Kong
| – |
|
|||
107
Two Sigma Advisers
New York
| – |
|
|||
|
AB
108
Amalgamated Bank
New York
| – |
|